VaxInnate makes promotions
This article was originally published in Scrip
Executive Summary
VaxInnate, a biotechnology firm developing a new vaccine technology, has announced two strategic promotions and two additions to its senior development team to help drive growth of the company's pipeline. Dr Lynda Tussey has been promoted to chief scientific officer from vice-president of R&D, while Bruce Weaver has been named vice-president of manufacturing following his time as director of process development. Also Dr Peter Fusco has joined the company as vice-president of R&D, and Dr Stephen Haworth has assumes the role of vice-president of clinical. Mr Weaver, Dr Fusco and Dr Haworth will join the company's senior management team.